No additional alternative technique was used before (i.e., rotablator, laser or other debulking devices) or after stenting (i.e., intracoronary radiation therapy). During the intervention, patients received heparin (12,000 to 15,000 IE intra-arterially) and aspirin (500 mg intravenously). Stent implantation of either a slotted-tube or multicellular type was performed either as loose stents firmly hand-crimped onto conventional angioplasty balloon catheters (n = 4,080) or pre-mounted on their commercially available delivery systems (n = 1,598). Various stent types were used: Multi-Link stent (n = 1,428; ACS-Guidant, Temecula, California), Inflow stent (n = 1,334; Inflow Dynamics, Munich, Germany), Palmaz-Schatz stent (n = 1,051; Johnson & Johnson Interventional Systems, Warren, New Jersey), Jostent (n = 735; JOMED, Rangendingen, Germany), Pura-A (n = 451; Devon Medical, Hamburg, Germany), NIR stent (n = 308; Scimed-Boston Scientific, Maple Grove, Minnesota) and several other types in <60 procedures (total n = 371). Procedural results were assessed by angiography only; no intravascular ultrasound studies were utilized. All patients were given ticlopidine (250 mg twice a day, Tiklyd, Sanofi-Winthrop, Munich, Germany) for four weeks in addition to aspirin (100 mg twice a day, indefinitely). Most patients received a loading regimen for ticlopidine with three doses of 500 mg, started as early as possible before or immediately after the intervention (<30 min after the procedure). The study period comprises the introduction of glycoprotein IIb/IIIa inhibitors. Overall, abciximab was administered in 1,943 procedures (34.2%); it increased from 7.4% in the first year to 64.8% in the last year to become routine for patients with acute coronary syndromes, with visible intracoronary thrombi, or with flow-limiting dissections or occlusion during the procedure.